Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO)

Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO)

Trial Category:
Melanoma
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members